Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C in Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT07379333Phase 3Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Hanmi Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07379333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379333.